DERM - デルミラ （Dermira Inc.）

SCOTTSDALE, Ariz., March 07, 2023 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage biopharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that management will participate in the 35 th Annual ROTH Conference, which is being held March 12-14, 2023.

SCOTTSDALE, Ariz., Nov. 03, 2022 (GLOBE NEWSWIRE) — Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical firm that focuses on the event and commercialization of pharmaceutical merchandise for […] The post Journey Medical Corporation to Announce Third Quarter 2022 appeared first on Businessfortnight .

Fortress Biotech Inc. (NASDAQ: FBIO) is a biopharmaceutical company focused on developing a range of high-potential treatments on its own and through its growing portfolio of subsidiaries and partner companies. With nine products already on the market and more than 30 programs in development, the biopharmaceutical company helps deliver innovative drug therapies to patients who have a wide range of diseases and disorders. Here are three of the most significant breakthrough developments it achieved this year. Checkpoint’s Cancer Immunotherapy Aims To Add Second Treatment Indication Checkpoint Therapeutics Inc. (NASDAQ: CKPT) announced positive interim results in June from a registration-enabling clinical trial of its anti-PD-L1 checkpoint inhibitor. The novel cancer immunotherapy is being studied as a possible treatment for advanced cutaneous squamous cell carcinoma (cSCC), a difficult-to-treat skin cancer. The current first-line treatment for cSCC is surgery to remove the tumor or radiation therapy to destroy the tumor.

In the last trading session, 50487.0 Journey Medical Corporation (NASDAQ:DERM) shares changed hands as the company’s beta touched 0. With the company’s per share price at $3.03 changed hands at -$0.17 or -5.46% during last session, the market valuation stood at $35.12M. DERM’s last price was a discount, traded about -236.63% off its 52-week high … Journey Medical Corporation (NASDAQ: DERM): Time To Buy Over The Next Few Months Read More »

SCOTTSDALE, Ariz., Nov. 03, 2022 (GLOBE NEWSWIRE) — Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical firm that focuses on the event and commercialization of pharmaceutical merchandise for […] The post Journey Medical Corporation to Announce Third Quarter 2022 appeared first on Businessfortnight .

Fortress Biotech Inc. (NASDAQ: FBIO) is a biopharmaceutical company focused on developing a range of high-potential treatments on its own and through its growing portfolio of subsidiaries and partner companies. With nine products already on the market and more than 30 programs in development, the biopharmaceutical company helps deliver innovative drug therapies to patients who have a wide range of diseases and disorders. Here are three of the most significant breakthrough developments it achieved this year. Checkpoint’s Cancer Immunotherapy Aims To Add Second Treatment Indication Checkpoint Therapeutics Inc. (NASDAQ: CKPT) announced positive interim results in June from a registration-enabling clinical trial of its anti-PD-L1 checkpoint inhibitor. The novel cancer immunotherapy is being studied as a possible treatment for advanced cutaneous squamous cell carcinoma (cSCC), a difficult-to-treat skin cancer. The current first-line treatment for cSCC is surgery to remove the tumor or radiation therapy to destroy the tumor.

In the last trading session, 50487.0 Journey Medical Corporation (NASDAQ:DERM) shares changed hands as the company’s beta touched 0. With the company’s per share price at $3.03 changed hands at -$0.17 or -5.46% during last session, the market valuation stood at $35.12M. DERM’s last price was a discount, traded about -236.63% off its 52-week high … Journey Medical Corporation (NASDAQ: DERM): Time To Buy Over The Next Few Months Read More »

SCOTTSDALE, Ariz., May 24, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Journey Medical and Padagis US LLC (“Padagis”) entered into a

In the last trading session, 50487.0 Journey Medical Corporation (NASDAQ:DERM) shares changed hands as the company’s beta touched 0. With the company’s per share price at $3.03 changed hands at -$0.17 or -5.46% during last session, the market valuation stood at $35.12M. DERM’s last price was a discount, traded about -236.63% off its 52-week high … Journey Medical Corporation (NASDAQ: DERM): Time To Buy Over The Next Few Months Read More »

SCOTTSDALE, Ariz., May 24, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that Journey Medical and Padagis US LLC (“Padagis”) entered into a

Journey Medical Corp (DERM) shares closed today at 1.4% above its 52 week low of $5.62, giving the company a market cap of $60M. The stock is currently down 40.0% year-to-date, down 40.0% over the past 12 months, and down 40.0% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 62.3% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -3669.7% The company's stock price performance over the past 12 months lags the peer average by 883.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

Journey Medical Corp (DERM) shares closed today at 1.4% above its 52 week low of $5.62, giving the company a market cap of $60M. The stock is currently down 40.0% year-to-date, down 40.0% over the past 12 months, and down 40.0% over the past five years. This week, the Dow Jones Industrial Average rose 1.6%, and the S&P 500 rose 2.3%. Trading Activity Trading volume this week was 61.4% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.0. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -3669.7% The company's stock price performance over the past 12 months lags the peer average by 883.7% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.

The global Acne Vulgaris Treatment market size is projected to a CAGR of 5.7% during 2021-2027. To examine the market''s effect forces and prospective prospects, the research includes an in-depth examination of the competitive landscape, product market size, product benchmarking,